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Background: Hepatitis delta virus (HDV) testing is recommended for all patients with hepatitis B virus
(HBV) infection. HDV infection is associated with severe liver disease and interferon is the only available
treatment.
Objectives: To determine the rate of anti-HDV antibody testing in HBV patients; and to describe the
epidemiology, clinical characteristics and management of HDV-infected patients at four hospitals in
London.
Study design: The anti-HDV testing rate was estimated by reviewing clinical and laboratory data. Cross-
sectional data collection identiﬁed HDV-infected patients who had attended the study centres between
2005 and 2012.
Results: At a centre with clinic-led anti-HDV testing, 40% (67/168) of HBV patients were tested. Recently
diagnosed HBV patients were more likely to be screened than those under long-term follow-up (62% vs
36%, P=0.01). At a centre with reﬂex laboratory testing, 99.4% (3543/3563) of ﬁrst hepatitis B surface
antigen positive samples were tested for anti-HDV. Across the four study centres there were 55 HDV-
infected patients, of whom 50 (91%) had immigrated to the UK and 27 (49%) had evidence of cirrhosis.
31 patients received interferon therapy for HDV with an end of treatment virological response observed
in 10 (32%).
Conclusions: The anti-HDV testing rate was low in a centre with clinic-led testing, but could not be eval-
uated in all centres. The HDV-infected patients were of diverse ethnicity, with extensive histological
evidence of liver disease and poor therapeutic responses. Future recommendations include reﬂex labo-
ratory testing algorithms and a prospective cohort study to optimise the investigation and management
of these patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Background
The worldwide prevalence of hepatitis delta virus (HDV) infec-
tion is estimated to be 5% of HBV-infected individuals. There are
endemic areas in Eastern and Southern Europe, Central and East-
ern Africa, the Amazon Basin, parts of Asia and the Middle East
[1]. HDV infection was previously thought to be rare in Northern
Europe and concentrated in high risk groups such as injection drug
users. However, a study by Cross et al. in a South London liver unit
http://dx.doi.org/10.1016/j.jcv.2015.02.011
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suggested an increase in anti-HDVantibody (anti-HDV)prevalence,
from 2.6% of HBV patients in the 1980s to 8.5% in the period from
2000 to 2006, and only 24% of HDV infections were associatedwith
injection drug use [2]. Tong et al. reported a lower HDV seropreva-
lence of 2% from2008 to 2010 in another London cohort of hepatitis
Bpatients, and this studyalsohighlighted the roleofmigration from
endemic countries [3]. Sentinel surveillance by the Health Protec-
tion Agency in England found the seroprevalence to be 3.7% of all
individualswhowere tested for anti-HDV in2011 [4]. TheEuropean
Association for the Study of the Liver (EASL) guidelines recommend
anti-HDV testing for all HBV-infected patients [5].
HDV infection is associated with higher rates of cirrhosis and
hepatocellular carcinoma than HBV infection alone and persist-
ing HDV replication is considered the most important predictor of
mortality [5]. Interferon is the only available treatment for HDV
infection but the optimal duration of therapy has not been estab-
lished and virological response rates are low. Although signiﬁcant
morbidity is attributed to this virus, there is a paucity of current
studies describing patientswith active HDV infection, as evidenced
by detectable HDV RNA.
2. Objectives
The aim of this study was two-fold: ﬁrstly, to determine the
rate of anti-HDV testing in HBV patients at four tertiary hospitals in
London; and secondly, to describe the epidemiology, clinical char-
acteristics and treatment of HDV-infected patients across the study
centres.
3. Study design
3.1. HDV testing
The rate of anti-HDV testingwas estimatedbydividing thenum-
ber of HBV patients attending clinic in a 3-month period who had
ever been tested for anti-HDV, by the total number of HBV patients
attendingclinicduring the sameperiod. Inaddition to theelectronic
results systems, clinic letters were reviewed to look for evidence
of previous testing elsewhere. If clinic information was unavail-
able, then laboratory datawere reviewed to determine the number
of ﬁrst hepatitis B surface antigen (HBsAg) positive samples that
were tested for anti-HDV.
3.2. HDV-infected patients
A multicentre cross-sectional study was conducted to charac-
terise patients with active HDV infection. Eligible patients were
identiﬁed by searching laboratory results systems for positive HDV
RNA results from the year 2000 onwards. The study included all
adult HBV patients who had attended a hepatology clinic at one of
the four centres between January 2005 and June 2012 and had at
least one blood sample with detectable HDV RNA. Individuals with
positive anti-HDV but no detectable HDV RNA were excluded as
they could not be determined to have active infection with HDV
viraemia. A data capture form was completed by members of the
Delta StudyGroupusing clinical and laboratory data extracted from
the patients’ case notes and electronic records.
3.3. Laboratory methods
Anti-HDV antibody testing was performed using the ETI-AB-
DELTAK-2 assay (DiaSorin, Saluggia, Italy). HDV RNA quanti-
tation was performed with a single-step quantitative reverse-
transcriptase polymerase chain reaction (RT-PCR) as previously
described by Ferns et al. [6]. Available samples were genotyped
using the following protocol, based on the method published by
Le Gal et al. [7]. HDV RNA was extracted from 140l of plasma
using the QIAamp Viral RNA Mini Kit (Qiagen, Manchester, UK).
The nucleic acid extract (20l) was ampliﬁed by a semi-nested PCR
using HDV primers located in the R′1 and R0 regions. First round
primers were 305s (5′ CTCCAGAGGACCCCTTCAGCGAAC 3′) [7]
and XHO hdv (5′ GAAGGAAGGCCCTCSGAGAACAAG 3′) and second
roundprimerswere 305s and1161as (5′ CCCGCGGGTTGGGGATGT-
GAACCC 3′) [7]. The ﬁrst round 50l mastermix contained 25l of
2× reaction mix buffer from the SuperScript® III One-Step RT-PCR
System (Life technologies
TM
), 0.8M of each ﬁrst round primer,
10l of water and 1l of with Platinum® Taq High Fidelity. Condi-
tions for ampliﬁcation were 50 ◦C for 30min, 95 ◦C for 15min and
then 2 cycles of 95 ◦C for 30 s, 50 ◦C for 45 s, 72 ◦C for 2min and
38 cycles of 95 ◦C for 30 s, 60 ◦C for 45 s, 72 ◦C for 90 s with a 7min
extensionat72 ◦C. TheTaqPCRmastermixkit (Qiagen)wasused for
the second roundwith 25l Qiagen 2× mastermix, 0.8Mof each
primer, 21l of water and 2l of ﬁrst round product. The second
round conditions were 95 ◦C for 10min, followed by 45 cycles of
95 ◦C for 30 s, 60 ◦C for 45 s, 72 ◦C for 1minwith a ﬁnal extension at
72 ◦C for 7min. Products of 856bpwere bi-directionally sequenced
using primers 305s and 1161as on an ABI 3130xl DNA analyzer.
The HDV sequences were then referenced to the BLAST database
(http://blast.ncbi.nlm.nih.gov) to determine the genotype.
3.4. Statistical analysis
The statistical analysis was performed using STATA version
11. Continuous variables were described by median and range or
interquartile range (IQR), and categorical variables by frequency
and percentage. Chi-square test was used to compare the rates of
anti-HDV testing in patients with recent HBV diagnoses and those
under long-term follow-up. Chi-square, Wilcoxon rank sum and
Fisher’s exact tests were used to compare the virological markers
and treatment of patients with and without cirrhosis.
4. Results
4.1. HDV testing
Data on the number of HBV patients reviewed in clinic were
available for one of the study centres (C1). At C1, HDV testing was
only performed if requested by the clinician and, in the three-
month period from June to August 2012, 168 HBV patients were
seen in the C1 clinics and 67 (40%) had ever been tested for anti-
HDV. Patients ﬁrst diagnosed with HBV infection in the preceding
sixmonthsweremore likely tohavehadHDV investigations (16/26,
62%) than those under long-term HBV follow-up (51/142, 36%,
P=0.01, Chi-square test). The seroprevalence of those tested at C1
was 6% (4/67). Two seropositive patients were also HDV RNA pos-
itive. At a second centre, C2, the number of HBV patients seen in
clinic was not recorded; however, reﬂex laboratory-led anti-HDV
testing of all ﬁrst HBsAg positive samples had been employed from
2001 to 2012. During this period, 99.4% (3543/3563) of ﬁrst HBsAg
positive samples were tested for anti-HDV and 4.5% (158/3543)
were seropositive. Thirty-two of these 158 seropositive patients
were also HDV RNA positive and so were included in the second
part of the study. The two other centres, C3 and C4, used clinic-led
testing but there were insufﬁcient data to determine the rate of
testing.
4.2. Patient characteristics
Across the four centres, 55 patients were identiﬁed as having
had active HDV infection during the study period. The group had a
median age of 40 years, IQR 31–51 years, and 33 (60%) were men.
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Table 1
Country of origin and HDV genotype of HDV-infected patients.
Country of originby region Number of patients(% of total) HDV genotype if knowna(number of patients)
Asia 21 (38%)
Afghanistan 4 (7.3%) 1 (n=2)
Mongolia 4 (7.3%) 1 (n=3)
Pakistan 4 (7.3%) 1 (n=1)
Turkey 4 (7.3%) 1 (n=1)
India 2 (3.6%) –
Bangladesh 1 (1.8%) –
Uzbekistan 1 (1.8%) –
Vietnam 1 (1.8%) –
Africa 11 (20%)
Ghana 2 (3.6%) 5 (n=1)
Nigeria 2 (3.6%) 1 (n=1)
Sierra Leone 2 (3.6%) –
Angola 1 (1.8%) 1 (n=1)
Congo 1 (1.8%) 5 (n=1)
The Gambia 1 (1.8%) 5 (n=1)
Liberia 1 (1.8%) 5 (n=1)
Africa (not speciﬁed) 1 (1.8%) 1 (n=1)
Eastern Europe/Russia 14 (25%)
Romania 7 (12.7%) 1 (n=2)
Bulgaria 3 (5.5%) –
Russia 3 (5.5%) 1 (n=2)
Latvia 1 (1.8%) 1 (n=1)
Rest of Europe 9 (16%)
United Kingdom 5 (9.1%) 1 (n=2); 5 (n=2)
Italy 3 (5.5%) 1 (n=2)
Portugal 1 (1.8%) –
a - Denotes HDV genotyping not done.
Fifty patients (91%) had immigrated to the UK and they originated
from 22 different countries (Table 1). The calendar years of both
HBV and HDV diagnoses could be determined for 49 patients and,
of these, 19 (39%) were diagnosed with both infections in the same
year. The median difference in years from HBV to HDV diagnoses
was 1 (range 0–25, IQR 0–8).
4.3. Virological markers
Themajorityofpatientswerehepatitis Be-antigen (HBeAg)neg-
ative (50/55 patients, 91%) and anti-HBe positive (44/55, 80%). The
medianHBV viral loadwas 0 IU/mL (IQR 0–519) for patients receiv-
ing HBV therapy and 66 IU/mL (IQR 0–483) for those who were
not treated for HBV. The median HBsAg level was 2947 IU/mL (IQR
1216–10761) for the 21 patients in whom quantitation was per-
formed. Quantitative HDV RNA results were determined for 19 of
the 55 HDV RNA positive patients with a median viral load of 5
million copies/mL. HDV genotyping was performed in 25 cases: 19
(76%) had HDV-1 infection and six patients had HDV-5 (see Table 1
for geographical distribution).
4.4. Liver disease
Seventeen patients (31%) had a clinical diagnosis of cirrhosis,
and a further three individuals had acute hepatic failure. Liver
biopsies were performed in 37 patients (67%) and the histologi-
cal staging ranged from mild to severe ﬁbrosis (Table 2). Of the
19 patients with documented histological grades, 3 had minimal
inﬂammation (grade 1–4), 12 mild (grade 5–8), 2 moderate (grade
9–12) and 2 had marked inﬂammation (grade 13–18).
4.5. Antiviral treatment
Overall, 31 patients (56%) received pegylated interferon alpha
therapy for HDV at a dose of 180microgrammes weekly via subcu-
taneous injection forbetween1and2years. Ten (10/31, 32%)hadan
end of treatment virological response (EOTVR), while the remain-
der failed therapywithdetectableHDVRNAat theendof treatment.
Themost common duration of therapywas around one year (26/31
patients, 9/26 had an EOTVR, 1/9 also had HBsAg seroconversion).
Five patients received longer courses of between 18 months and
2 years but only one of them experienced an EOTVR. This patient
also had HBsAg seroconversion and the declining HBsAg appeared
to be the reason for prolonging therapy in this case. No patients
discontinued therapy prematurely. HDV treatment and outcomes
were also examined for two subgroups: group 1 were individuals
who did not have a clinical diagnosis of cirrhosis and had stage 1–4
disease on liver biopsy if performed, and group 2 comprised those
with a clinical diagnosis of cirrhosis and/or stage 5–6 liver disease
(Table 3).
Five of the patients who did not have an EOTVR following ini-
tial HDV treatment went on to have a second course of interferon
but none cleared the HDV infection. None of the three patients
with acute liver failure were treated for HDV infection but two
Table 2
Liver biopsy ﬁndings of HDV-infected patients.
Liver biopsy result All patientsn=55 Treated HDVn=31 Untreated HDVn=24
Stages 1–2 8 (15%) 5 (16%) 3 (13%)
Stages 3–4 14 (25%) 10 (32%) 4 (17%)
Stages 5–6 15 (27%) 9 (29%) 6 (25%)
Biopsy not done 15 (27%) 5 (16%) 10 (42%)
Biopsy data missing/unknown 3 (5%) 2 (6%) 1 (4%)
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Table 3
Comparison of HDV-infected patients with and without cirrhosis.
Group 1: No cirrhosisa(n=26) Group 2: Cirrhosis(n=27) P value for comparison
Virological markers
HBeAg positive (n, %) 1 (4%) 4 (15%) 0.35b
Anti-HBe positive (n, %) 23 (88%) 21 (78%) 0.30c
Median log10 HDV RNA (IQR) 8.1 (7.5–8.5) 6.2 (6.0–6.3) 0.007d
Antiviral treatment
Received HBV treatment, n (% total) 5 (19%) 17 (63%) 0.001c
Received HDV treatment, n (% total) 14 (54%) 16 (59%) 0.69c
HDV EOTVR, n (% treated for HDV) 6 (43%) 3 (19%) 0.25c
Clinical outcome
Died 0 1 –
Awaiting liver transplant 0 2 –
Decompensated disease,not suitable for transplant 0 1 –
Transferred care 1 1 –
Lost to follow-up 1 0 –
a There was insufﬁcient information to categorise two of the HDV-infected patients into either group.
b Two-tailed P value from Fisher’s exact test.
c Two-tailed P value from Chi-square test.
d Two-tailed P value from Wilcoxon rank sum test used to compare quantitative HDV results (10 patients in group 1 and 8 patients in group 2).
received nucleos(t)ide inhibitor therapy for HBV. With regard to
HBV treatment, 9 of the 31 patients treated for HDV also com-
menced nucleos(t)ide inhibitor therapy for HBV, almost all starting
after the course of interferon. Of the 24 patients who were not
treated for HDV, 13 received therapy for HBV. Around half of the
HBV-treated patients had tenofovir; other agents used included
lamivudine, entecavir and adefovir.
5. Discussion
The rate of anti-HDV testing was low in a centre with clinic-led
investigations. Recently diagnosed HBV patients were more likely
to be tested than those under long term follow-up, but only repre-
sented a minority of outpatients at this site. In contrast, the centre
with a reﬂex laboratory algorithm achieved anti-HDV testing of
almost all ﬁrst HBsAg positive samples over a 12-year period. A
direct comparison of testing at these two centres was not possible
due to a lack of information onHBV clinic attendees. The seropreva-
lence results of 6% and 4.5%were similar to theworldwide estimate
of 5%, and higher than most London estimates.
This is one of the largest studies of patients with active HDV
infection in theUK.We found a relatively young patient group, sim-
ilar to other studies in London [2–4]. There was diverse ethnicity
within our patient populations, reﬂecting the wide global distri-
bution of HDV. The majority had emigrated from endemic areas,
and this highlights the importance of screening high-risk groups
for blood-borne viruses. HDV infection was diagnosed after HBV
in over half of the patients and this needs further exploration to
determinewhether there is delayed diagnosis of HDV or if superin-
fection occurs subsequently. Most of the viruses sequenced in this
study were HDV-1, which is the most prevalent of the eight delta
genotypes foundworldwide [1]. Genotyping of all HDVcaseswould
allow a better understanding of the geographical distribution and
permit comparison of virological responses between genotypes.
The study participants had a considerable burden of liver dis-
ease, with around half having either clinically diagnosed or biopsy
proven cirrhosis. The true ﬁgure may be higher as one third of
patients were not fully evaluated with a liver biopsy. Despite the
hepatic pathology observed, interferon therapy was given to just
over half of patients. The reasons for not treating were unclear
but may reﬂect the contraindications and risk of adverse effects
associated with interferon, as well as the low chance of success,
deterring both patients and clinicians. Patients with cirrhosis were
more likely to be treated for HBV than patients without cirrho-
sis but there did not appear to be a difference in the proportions
treated forHDV. The patientswith cirrhosis appeared to have lower
pre-treatment levels of HDV viraemia than those without cirrho-
sis, however, only a minority of patients had quantitative RNA
results available for analysis. The end of treatment RNA result was
used to assess response as the concept of a “sustained” virologi-
cal response in HDV infection has been brought into question by
reports of patients who experienced late relapses following inter-
feron therapy [9]. Only one third of individuals who received HDV
treatment experienced a virological response, and this ﬁnding is
consistent with the 25–40% rate cited by EASL [5]. There were
insufﬁcientnumbers todemonstratea signiﬁcantdifference inviro-
logical response between those with and without cirrhosis.
The limitationsof this study include theuseof retrospectivedata
collection by several clinicians using different laboratory systems.
Insufﬁcient data management systems prohibited a comparison of
HDV testing across the study centres. HBVpatientswere not always
tested for anti-HDVandnot all seropositive patientswere tested for
HDV RNA, therefore incomplete testing coverage makes it likely
that some HDV-infected patients were not ascertained. Further-
more, selective HDV investigations may have biased the sample
towards including those with more severe disease.
As a result of this study, future recommendations include reﬂex
anti-HDV testing of HBV patients in all centres and standardised
HDVRNA testing of seropositive patients using theWHOHDV stan-
dard (PEI code7657/12,GenBankaccessionnumberHQ005371) [8].
TheDelta StudyGrouphas beenestablished as amulticentre collab-
oration for the diagnosis, characterisation andmanagement ofHDV
patients. A prospective cohort study and a comprehensive database
are planned to further delineate the natural history and treatment
outcomes of this disease. There is a clear need for more efﬁcacious
and tolerable treatment options and there has been encouraging
progress in this ﬁeldwith the identiﬁcation of theHBV receptor and
the development of entry inhibitors [10]. A well-described cohort
would facilitate clinical trials and enable clinicians to readily iden-
tify patients who could beneﬁt from new therapeutic modalities.
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